2023年10月，赛诺菲以5亿美元的首付款及最高达10亿美元的里程碑付款与梯瓦就该药的开发和商业化达成了合作。In October 2023, Sanofi (SNY.US) reached an agreement with Teva for the development and commercialization of the drug with an upfront payment of $0.5 billion and milestone payments of up to $1 billion.
According to the Zhitong Finance APP, on December 17, Sanofi (SNY.US) and Teva announced that the Phase IIb RELIEVE UCCD study achieved its primary endpoint, which aimed to evaluate the efficacy, safety, pharmacokinetics, and tolerability of duvakitug in treating patients with moderate to severe ulcerative colitis (UC) and Crohn's disease (CD). The results showed that patients in the duvakitug treatment group achieved a higher clinical remission rate compared to the placebo, indicating the potential of a best-in-class therapy.
Duvakitug is a humanized IgG1-λ2 monoclonal antibody targeting tumor necrosis factor (TNF)-like ligand 1A (TL1A) developed by Teva.
In October 2023, Sanofi reached an agreement with Teva for the development and commercialization of the drug with an upfront payment of $0.5 billion and milestone payments of up to $1 billion.
